CareDx, Inc (CDNA)
NASDAQ: CDNA · Real-Time Price · USD
22.37
+0.31 (1.41%)
At close: Nov 20, 2024, 4:00 PM
22.52
+0.15 (0.67%)
Pre-market: Nov 21, 2024, 4:00 AM EST
CareDx Revenue
CareDx had revenue of $82.88M in the quarter ending September 30, 2024, with 23.35% growth. This brings the company's revenue in the last twelve months to $312.78M, up 5.26% year-over-year. In the year 2023, CareDx had annual revenue of $280.32M, down -12.89%.
Revenue (ttm)
$312.78M
Revenue Growth
+5.26%
P/S Ratio
3.76
Revenue / Employee
$486,431
Employees
643
Market Cap
1.20B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 280.32M | -41.47M | -12.89% |
Dec 31, 2022 | 321.79M | 25.40M | 8.57% |
Dec 31, 2021 | 296.40M | 104.20M | 54.22% |
Dec 31, 2020 | 192.19M | 65.13M | 51.25% |
Dec 31, 2019 | 127.07M | 50.50M | 65.95% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pediatrix Medical Group | 2.01B |
Progyny | 1.14B |
Innoviva | 352.75M |
Maravai LifeSciences Holdings | 276.92M |
Aurinia Pharmaceuticals | 220.36M |
Arcutis Biotherapeutics | 138.71M |
CDNA News
- 9 days ago - CareDx to Participate in Upcoming Investor Conferences - Business Wire
- 16 days ago - CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 16 days ago - CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance - Business Wire
- 26 days ago - CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA - Accesswire
- 4 weeks ago - CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C Technology - Business Wire
- 4 weeks ago - CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting - Business Wire
- 5 weeks ago - CareDx, JD.com And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 5 weeks ago - CareDx Reports Preliminary Financial Results for Third Quarter 2024 - Business Wire